Competitor Analysis: Staphylococcus aureus Vaccines and Therapeutics (Antibodies, Antibiotics, Anti-Infectives)
Novel Prophylactic and Therapeutic Approaches to Manage Staphylococcus aureus (S. aureus) Infe ctions
Staphylococcus aureus disease is the leading cause of surgical site infections and infections that arise within hospital Intensive Care Units. Despite a clear and growing medical need, the pipeline for new antibiotics is drying up. Many pharmaceutical companies have abandoned antimicrobial research. In the meantime, bacteria are becoming more resistant to current antibiotics, with fewer new drugs being approved.
The present Competitive Intelligence Report about prophylaxis and therapy of S. aureus infections provides a competitor evaluation in the field of new molecules for prevention or treatment of Staphylococcus aureus infections as of October 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Staphylococcal aureus infections represent an enormous burden to public health systems. Traditionally restricted to the hospital setting as nosocomial infections, highly virulent strains have recently emerged in outside healthcare settings. Together with the increasing resistance to many antibacterials in a wide variety of staphylococcal strains, development of vaccines or specific and potent therapies for staphylococcal diseases raised increasing interest . Finding a vaccine for staphylococci is not trivial, as protective immunity to staphylococcal infections does not appear to exist at a significant degree. Promising results from novel approaches based on the combination of systematically selected antigens have been reported.
Passive immunotherapy with monoclonal therapeutic antibodies against S.aureus is another means to approach specific therapy of staphylococcal. While anti-staphylococcal purified polyclonal immunoglobulins are not recommended for prevention of staphylococcal infections in preterm or VLBW neonates, monoclonal antibodies are currently emerging and are in early development. Although not specific, bactericidal proteins and peptides with activity against S. aureus are in preclinical and clinical development. More targeted and improved antibiotics are also in development.
The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines and small molecules for prevention and treatment of Staphylococcus aureus infections. In addition, the report lists company-specific R&D pipelines of S. aureus vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Staphylococcus aureus disease is the leading cause of surgical site infections and infections that arise within hospital Intensive Care Units. Despite a clear and growing medical need, the pipeline for new antibiotics is drying up. Many pharmaceutical companies have abandoned antimicrobial research. In the meantime, bacteria are becoming more resistant to current antibiotics, with fewer new drugs being approved.
The present Competitive Intelligence Report about prophylaxis and therapy of S. aureus infections provides a competitor evaluation in the field of new molecules for prevention or treatment of Staphylococcus aureus infections as of October 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Staphylococcal aureus infections represent an enormous burden to public health systems. Traditionally restricted to the hospital setting as nosocomial infections, highly virulent strains have recently emerged in outside healthcare settings. Together with the increasing resistance to many antibacterials in a wide variety of staphylococcal strains, development of vaccines or specific and potent therapies for staphylococcal diseases raised increasing interest . Finding a vaccine for staphylococci is not trivial, as protective immunity to staphylococcal infections does not appear to exist at a significant degree. Promising results from novel approaches based on the combination of systematically selected antigens have been reported.
Passive immunotherapy with monoclonal therapeutic antibodies against S.aureus is another means to approach specific therapy of staphylococcal. While anti-staphylococcal purified polyclonal immunoglobulins are not recommended for prevention of staphylococcal infections in preterm or VLBW neonates, monoclonal antibodies are currently emerging and are in early development. Although not specific, bactericidal proteins and peptides with activity against S. aureus are in preclinical and clinical development. More targeted and improved antibiotics are also in development.
The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines and small molecules for prevention and treatment of Staphylococcus aureus infections. In addition, the report lists company-specific R&D pipelines of S. aureus vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
- S. aureus Vaccines
- S. aureus Antibodies
- S. aureus Antibiotics
- S. aureus Antiseptics & Anti-Infectives
- Corporate S. aureus Vaccines & Therapeutics R&D Pipelines
